AAPL VS ARVN Stock Comparison
Performance
AAPL100/100
100/100
AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.
ARVN10/100
10/100
ARVN returned -64.85% in the last 12 months. Based on SPY's performance of -13.04%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
AAPL78/100
78/100
38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.
ARVN75/100
75/100
3 analysts offer 12-month price targets for ARVN. Together, they have an average target of 73.25, the most optimistic target put ARVN at 123 within 12-months and the most pessimistic has ARVN at 24.
Sentiment
AAPL70/100
70/100
AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.
ARVN
"Sentiment" not found for ARVN
Technicals
AAPL18/100
18/100
AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.
ARVN64/100
64/100
ARVN receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
AAPL100/100
100/100
AAPL has missed earnings 1 times in the last 20 quarters.
ARVN10/100
10/100
ARVN has missed earnings 14 times in the last 20 quarters.
Profit
AAPL76/100
76/100
Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.
ARVN10/100
10/100
Out of the last 20 quarters, ARVN has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
AAPL45/100
45/100
AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
ARVN41/100
41/100
ARVN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Dividend
AAPL50/100
50/100
AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.
ARVN
"Dividend" not found for ARVN
All score calculations are broken down here to help you make more informed investing decisions
Apple Inc. Summary
Nasdaq / AAPL
Technology
Consumer Electronics
Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.
Arvinas, Inc Summary
Nasdaq / ARVN
Healthcare
Biotechnology
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare AAPL to other companies in the same or a similar industry.